These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 8103318)
1. In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy. Celerier P; Fleischmann M; Basset-Seguin N; Thill L; Bureau B; Litoux P; Dréno B Arch Dermatol; 1993 Sep; 129(9):1136-40. PubMed ID: 8103318 [TBL] [Abstract][Full Text] [Related]
2. Keratinocyte-lymphocyte interaction in cutaneous T-cell lymphoma. Modulation of keratinocyte antigen My7 by a soluble factor produced by T lymphocytes. Célérier P; Bureau B; Litoux P; Dréno B Arch Dermatol; 1997 Jul; 133(7):837-40. PubMed ID: 9236521 [TBL] [Abstract][Full Text] [Related]
3. Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas. Dreno B; Fleischmann M; Valard S; Godefroy W; Bureau B; Stadler JF; Litoux P Br J Dermatol; 1992 Apr; 126(4):320-3. PubMed ID: 1349233 [TBL] [Abstract][Full Text] [Related]
4. MY7 monoclonal antibody for diagnosis of cutaneous T-cell lymphoma. Dreno B; Bureau B; Stalder JF; Litoux P Arch Dermatol; 1990 Nov; 126(11):1454-6. PubMed ID: 2146925 [TBL] [Abstract][Full Text] [Related]
5. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Dréno B Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250 [TBL] [Abstract][Full Text] [Related]
6. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188 [TBL] [Abstract][Full Text] [Related]
7. Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. Sarris AH; Daliani D; Ulmer R; Crow M; Broxmeyer HE; Pugh W; Reiss M; Cabanillas F; Deisseroth AB; Duvic M Leuk Lymphoma; 1996 Dec; 24(1-2):103-10. PubMed ID: 9049966 [TBL] [Abstract][Full Text] [Related]
8. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. Tensen CP; Vermeer MH; van der Stoop PM; van Beek P; Scheper RJ; Boorsma DM; Willemze R J Invest Dermatol; 1998 Aug; 111(2):222-6. PubMed ID: 9699721 [TBL] [Abstract][Full Text] [Related]
9. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Sarris AH; Daliani D; Ulmer R; Crow M; Broxmeyer HE; Reiss M; Karasavvas N; Zelenetz AD; Pugh W; Cabanillas F; Deisseroth AB; Duvic M Clin Cancer Res; 1997 Feb; 3(2):169-77. PubMed ID: 9815669 [TBL] [Abstract][Full Text] [Related]
10. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782 [TBL] [Abstract][Full Text] [Related]
11. Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. Huang BB; Bonish BK; Chaturvedi V; Qin JZ; Nickoloff BJ J Invest Dermatol; 2001 Feb; 116(2):305-12. PubMed ID: 11180008 [TBL] [Abstract][Full Text] [Related]
12. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352 [TBL] [Abstract][Full Text] [Related]
13. Expression of class II major histocompatibility antigens by keratinocytes in cutaneous T cell lymphoma. Wood GS; Michie SA; Durden F; Hoppe RT; Warnke RA Int J Dermatol; 1994 May; 33(5):346-50. PubMed ID: 8039974 [TBL] [Abstract][Full Text] [Related]
14. [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma]. Otte HG; Herges A; Stadler R Hautarzt; 1992 Nov; 43(11):695-9. PubMed ID: 1468931 [TBL] [Abstract][Full Text] [Related]
15. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. Olsen EA; Rosen ST; Vollmer RT; Variakojis D; Roenigk HH; Diab N; Zeffren J J Am Acad Dermatol; 1989 Mar; 20(3):395-407. PubMed ID: 2783939 [TBL] [Abstract][Full Text] [Related]
16. About the cutaneous targets of bexarotene in CTCL patients. Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753 [TBL] [Abstract][Full Text] [Related]
17. CD13 and TCR clone: markers of early mycosis fungoides. Bernier C; Nguyen JM; Quéreux G; Renault JJ; Bureau B; Dreno B Acta Derm Venereol; 2007; 87(2):155-9. PubMed ID: 17340024 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Edelson RL Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563 [TBL] [Abstract][Full Text] [Related]
19. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis. Lee CH; Mamelak AJ; Vonderheid EC Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344 [TBL] [Abstract][Full Text] [Related]
20. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]